Last updated: October 13, 2026
Bumetanide is a mature generic loop diuretic with limited commercial differentiation, low unit pricing, and no meaningful remaining U.S. market exclusivity. The product competes primarily with furosemide and torsemide in heart failure, renal disease, and edema treatment. Its commercial value is concentrated in hospital injection supply, generic tablets, and institutional purchasing rather than branded pharmaceutical sales.
Molecule-specific revenue data are not publicly reported by major manufacturers. The financial trajectory is therefore best assessed through FDA approval history, generic competition, dosage-form economics, prescribing demand, supply conditions, and reimbursement data.
What is bumetanide and how is it used?
Bumetanide is an oral and injectable loop diuretic marketed historically in the United States under the brand name Bumex. It inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, producing rapid diuresis.
The main approved and routine clinical uses include:
- Edema associated with congestive heart failure
- Hepatic disease
- Renal disease, including nephrotic syndrome
- Acute or chronic fluid overload requiring parenteral treatment
U.S. dosage forms include tablets in 0.5 mg, 1 mg, and 2 mg strengths and an injection commonly supplied at 0.25 mg/mL. The injectable product is used when oral administration is impractical or when rapid diuresis is required.
The FDA approved Bumex in the early 1980s. The product is now a mature generic medicine rather than a branded growth product (U.S. Food and Drug Administration [FDA], n.d.-a).
What is the FDA regulatory status of bumetanide?
Bumetanide remains an FDA-approved prescription drug available through abbreviated new drug applications and legacy branded approval pathways.
| Regulatory attribute |
Status |
| Active ingredient |
Bumetanide |
| Drug class |
Loop diuretic |
| U.S. route |
Oral and intravenous/intramuscular injection |
| Common tablet strengths |
0.5 mg, 1 mg, 2 mg |
| Common injection strength |
0.25 mg/mL |
| Original U.S. approval period |
Early 1980s |
| Regulatory pathway today |
Generic ANDA products and legacy NDA products |
| Reference brand |
Bumex |
| Biosimilar pathway |
Not applicable |
| Controlled-substance status |
Not a controlled substance |
| Major safety constraints |
Volume depletion, electrolyte abnormalities, hypotension, ototoxicity risk at excessive exposure |
FDA labeling requires monitoring of fluid balance, renal function, electrolytes, and blood pressure. Hypokalemia, hyponatremia, hypomagnesemia, dehydration, and worsening renal function are relevant commercial and clinical considerations because they influence physician selection and hospital protocols (FDA, n.d.-b).
What is the Orange Book status of bumetanide?
Bumetanide has no commercially meaningful active ingredient exclusivity in the United States. Its original brand approval and any associated exclusivity periods expired decades ago.
The FDA Orange Book is the principal source for approved drug products, therapeutic-equivalence evaluations, and listed patent or exclusivity information. For a mature generic product such as bumetanide, the relevant commercial protection is generally limited to ANDA approval, manufacturing capability, supply reliability, and purchasing contracts rather than patent exclusion (FDA, 2024).
Are active patents listed for bumetanide?
No active composition-of-matter patent is commercially relevant to current U.S. bumetanide sales. The underlying molecule was approved more than 40 years ago, placing any original compound patent well beyond its ordinary U.S. patent term.
The practical patent profile is:
| Patent category |
Commercial position |
| Composition-of-matter patent |
Expired |
| Original formulation patent |
Expired or commercially immaterial |
| Brand exclusivity |
Expired |
| Orange Book-listed blocking patent |
No material current barrier identified |
| Method-of-use patents |
No widely recognized blocking patent position for routine approved uses |
| Manufacturing patents |
Potentially relevant to individual suppliers but not generally market-blocking |
| Pediatric exclusivity |
Not a current commercial barrier |
| Orphan-drug exclusivity |
Not applicable to the core product |
A patent may still exist around a specific process, formulation, packaging configuration, or combination product. Such patents would not restore exclusivity to standard bumetanide tablets or injection unless they covered the commercially necessary product and survived validity and infringement challenges.
When did bumetanide lose exclusivity?
Bumetanide lost practical U.S. exclusivity many years ago after generic entry. The brand’s commercial protection is no longer a meaningful determinant of market access.
Bumetanide exclusivity timeline
| Period |
Event |
| Early 1980s |
FDA approval of Bumex and U.S. commercial launch |
| Late 1980s onward |
Generic competition becomes possible after expiration of original protections |
| 1990s-2000s |
Product transitions to mature generic status |
| Current market |
Multiple generic suppliers, low differentiation, no meaningful brand exclusivity |
Exact historical generic-entry dates vary by dosage form and manufacturer. FDA approval records and Orange Book listings should be used for product-specific ANDA histories (FDA, n.d.-a; FDA, 2024).
How many patents cover bumetanide?
No material active U.S. patent estate covers the standard bumetanide molecule as a commercial product. The relevant number for market access is effectively zero for blocking composition patents.
A broader patent search could identify:
- Process patents
- Crystalline-form claims
- Injectable formulation claims
- Drug-delivery systems
- Combination therapies
- Veterinary or non-U.S. applications
Those categories do not equate to a blocking patent estate for ordinary U.S. generic tablets or injectable bumetanide. Patent risk is therefore substantially lower than for recently approved small molecules or reformulated specialty products.
Are there Paragraph IV challenges for bumetanide?
Paragraph IV litigation is not a meaningful current feature of the standard bumetanide market. Paragraph IV challenges arise when an ANDA applicant seeks approval before expiration of an Orange Book-listed patent and certifies that the patent is invalid, unenforceable, or not infringed.
Because bumetanide has no commercially relevant blocking patent position, new Paragraph IV disputes are unlikely to affect routine market entry. Generic applicants instead face ordinary ANDA review, bioequivalence requirements, chemistry and manufacturing controls, facility inspections, and possible product-specific labeling obligations (FDA, n.d.-c).
The litigation profile differs sharply from newer drugs:
| Issue |
Bumetanide |
Recently launched branded drug |
| Patent challenge frequency |
Low |
Often high |
| Hatch-Waxman litigation |
Limited practical relevance |
Frequently central to launch timing |
| Settlement risk |
Minimal |
Can materially delay generic entry |
| 180-day generic exclusivity value |
Low because of mature competition |
Potentially significant |
| Brand settlement exposure |
Minimal |
Potentially substantial |
What formulations are protected by bumetanide patents?
No standard bumetanide formulation has a commercially significant remaining U.S. patent moat. The conventional products are immediate-release tablets and injectable solutions.
Oral tablets
Generic tablets are relatively easy to manufacture compared with modified-release or complex drug-delivery products. The principal barriers are bioequivalence, content uniformity, stability, packaging, and reliable supply of active pharmaceutical ingredient.
Injectable bumetanide
Injection manufacturing has higher operational risk than tablet manufacturing because suppliers must meet sterile-production, particulate, container-closure, sterility, endotoxin, and stability requirements. These requirements can narrow the supplier base even when no patent protection exists.
The injectable market can therefore experience temporary supply constraints without any patent-driven exclusivity. FDA drug-shortage records and manufacturer notices are more relevant to near-term availability than patent litigation (FDA, n.d.-d).
Reformulations and combination products
There is no widely adopted, high-value bumetanide reformulation comparable to long-acting delivery systems or branded combination products. Any new reformulation would need to demonstrate clinical and commercial advantages sufficient to offset the low price of conventional loop diuretics.
How does bumetanide compare with furosemide and torsemide?
Furosemide is the dominant reference competitor by clinical familiarity, breadth of dosage forms, and historical use. Torsemide competes through oral pharmacokinetic characteristics and growing interest in heart-failure management. Bumetanide occupies a smaller but clinically important position, particularly when a patient has inadequate response to furosemide or requires a potent diuretic at a low dose.
| Attribute |
Bumetanide |
Furosemide |
Torsemide |
| Drug class |
Loop diuretic |
Loop diuretic |
Loop diuretic |
| Oral dosage |
Common |
Common |
Common |
| Injectable use |
Established |
Established |
Less central in acute hospital use |
| Commercial maturity |
Very mature generic |
Very mature generic |
Mature generic |
| Relative market scale |
Smaller |
Largest among the three |
Smaller than furosemide |
| Main advantage |
Potency at low milligram doses and clinical familiarity |
Broad availability and extensive experience |
Oral pharmacokinetic profile |
| Main limitation |
Small market and limited differentiation |
Variable oral absorption |
Lower institutional penetration in some settings |
| Patent-based differentiation |
None material |
None material |
None material |
A commonly used clinical conversion is approximately 1 mg bumetanide to 40 mg furosemide, although equivalence depends on route, patient status, renal function, and clinical response. Prescribers generally titrate to effect rather than rely solely on fixed conversion ratios.
Which companies manufacture or market bumetanide?
Bumetanide is supplied by a fragmented group of generic manufacturers and contract manufacturers. The specific supplier mix changes as products are approved, discontinued, acquired, or placed on back order.
The commercial categories are:
- Generic tablet manufacturers
- Sterile injectable manufacturers
- Hospital and institutional wholesalers
- Contract manufacturing organizations
- Legacy brand or authorized-generic suppliers, where available
The market is not controlled by a single innovator company. Supplier share is difficult to determine because private manufacturers generally do not disclose bumetanide revenue, unit volume, or product-level gross margin.
What is the market size and financial trajectory for bumetanide?
Public company filings do not typically report bumetanide revenue separately. The product is usually included within broad portfolios such as generic injectables, cardiovascular medicines, hospital products, or established pharmaceuticals.
The financial trajectory is therefore structurally mature:
| Financial driver |
Direction |
| Brand revenue |
Negligible or absent in the standard U.S. market |
| Generic unit demand |
Stable, with clinical fluctuations |
| Unit price |
Low and subject to purchasing pressure |
| Gross margin |
Higher for reliable sterile supply than for commodity tablets |
| Revenue growth |
Limited without geographic expansion or supply disruption |
| R&D spending |
Minimal for the base molecule |
| Commercial value |
Concentrated in manufacturing scale and supply reliability |
| Pricing power |
Weak |
| Acquisition value |
Portfolio-based rather than molecule-based |
Demand is supported by persistent use in heart failure, kidney disease, cirrhosis, and hospital fluid management. The addressable patient population is large, but bumetanide captures only a portion of loop-diuretic prescribing.
The highest-value commercial opportunity is generally not a new bumetanide indication. It is dependable supply of sterile injection, efficient production, hospital contracting, and portfolio bundling with other generic injectable products.
What generic entry risks exist for bumetanide?
Generic entry risk is effectively exhausted for standard bumetanide products. The commercial risks run in the opposite direction: supplier withdrawal, manufacturing failure, quality recalls, raw-material disruption, and hospital substitution.
Key risks for manufacturers
- Price compression from multiple suppliers
- Low switching costs for buyers
- Hospital group purchasing pressure
- Sterile manufacturing failures
- Shortage-driven regulatory scrutiny
- Low return on formulation investment
- Product discontinuation if margins fall below manufacturing cost
Key risks for investors and licensees
- No patent-protected upside
- Limited ability to raise price without losing contracts
- Weak visibility into molecule-specific sales
- Dependence on portfolio scale
- Exposure to FDA inspection and remediation costs
- Potential substitution by furosemide or torsemide
What patent litigation and settlement agreements affect bumetanide?
No significant current U.S. patent litigation or Hatch-Waxman settlement is central to the standard bumetanide market. This differs from protected branded drugs, where litigation and settlement agreements can determine generic entry dates and billions of dollars in revenue exposure.
For bumetanide, commercial disputes are more likely to involve:
- Product quality
- Manufacturing defects
- Supply contracts
- Hospital purchasing
- Regulatory compliance
- Trademark or labeling issues
Patent litigation would become commercially relevant only if a supplier introduced a differentiated formulation, delivery system, or combination product with enforceable claims.
How strong is the bumetanide patent estate?
The patent estate is weak for the base molecule and standard dosage forms. Its strength is best characterized as follows:
| Factor |
Assessment |
| Remaining composition protection |
None of practical importance |
| Formulation protection |
Limited |
| Method-of-use protection |
Limited for routine indications |
| Manufacturing barriers |
Moderate for sterile injection |
| Regulatory barrier |
Moderate for new ANDA applicants |
| Market concentration |
Potentially higher in injection than tablets |
| Pricing protection |
Weak |
| Litigation deterrence |
Low |
| Long-term defensibility |
Low |
The distinction between patent strength and manufacturing difficulty is important. Injectable bumetanide may be operationally difficult to supply while remaining legally unprotected.
What is the commercial outlook for bumetanide?
Bumetanide should remain a stable, low-growth generic product. Demand is likely to track the prevalence of heart failure, chronic kidney disease, cirrhosis, hospitalization, and acute fluid overload.
The most probable commercial scenarios are:
Base case
Generic tablets remain available at low prices, while several suppliers compete on cost and distribution. Revenue stays stable or declines modestly in nominal terms.
Supply-constrained case
A sterile manufacturer exits or experiences a quality problem. Temporary shortages improve pricing and supplier economics, but the effect is episodic rather than durable.
Portfolio-growth case
A manufacturer increases sales by bundling bumetanide with other hospital injectables, expanding distribution, or winning institutional contracts. Growth comes from portfolio execution, not molecule-level innovation.
Reformulation case
A company develops a differentiated delivery product or combination therapy. The opportunity would require clinical evidence, regulatory investment, and a reimbursement rationale that conventional generic bumetanide does not currently provide.
Key Takeaways
- Bumetanide is a mature generic loop diuretic with no meaningful remaining U.S. market exclusivity.
- The active ingredient, conventional tablets, and standard injection are not protected by a commercially significant patent estate.
- Paragraph IV litigation and settlement agreements are not material to current standard-product competition.
- Furosemide is the principal competitor by market scale; torsemide is another clinically relevant alternative.
- Tablet economics are highly commoditized. Sterile injection supply has greater operational value because manufacturing barriers are higher.
- Public companies generally do not disclose bumetanide-specific revenue, preventing reliable molecule-level market-size calculations.
- The financial trajectory is stable to low-growth, with value determined by manufacturing efficiency, hospital contracts, supply reliability, and portfolio scale.
- FDA regulatory compliance and shortage management are more important than patent enforcement.
- Biosimilar risk is irrelevant because bumetanide is a small-molecule drug, not a biologic.
- Any meaningful upside would require differentiated formulation, geographic expansion, or supply disruption.
FAQs About Bumetanide Market and Patent Status
Is Bumex still a protected brand drug?
No. Bumex is a legacy brand, and the standard bumetanide market is supplied primarily through generic products without meaningful current brand exclusivity.
Does bumetanide have biosimilar competition?
No. Biosimilars apply to biologic products. Bumetanide is a chemically synthesized small molecule and competes through generic ANDA products.
Can a generic company obtain 180-day exclusivity for bumetanide?
An ANDA applicant could theoretically qualify for generic exclusivity under applicable FDA rules, but the commercial value would be limited in a mature market with longstanding generic availability.
Is injectable bumetanide more commercially attractive than tablets?
Usually. Injectable bumetanide has higher manufacturing and quality-control requirements, fewer practical suppliers, and greater exposure to hospital supply dynamics. Those factors can support better economics than commodity tablets, although no patent protection exists.
Could a new bumetanide formulation create meaningful exclusivity?
Potentially, but only if the formulation obtained enforceable patent protection or regulatory exclusivity and delivered a clinically relevant advantage. Conventional immediate-release tablets and standard injection do not provide that protection.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-b). Bumetanide prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application ANDA process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (n.d.-d). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages】【。
